Navigation Links
Astellas Names Head of Global R&D Operations
Date:6/10/2009

DEERFIELD, Ill., June 10 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Peter Carberry, has been hired as the senior vice president and head of global development operations. Carberry is responsible for enhancing the effectiveness and efficiency of the integrated global operational platform including the data sciences and clinical operations organizations.

"We are pleased that Peter has joined Astellas and we know that he will contribute significantly to the development of innovative products," said Dr. Steven Ryder, president of APGD. "Peter is one of several key hires at APGD that were brought on to strengthen and accelerate our research and development function."

Prior to joining Astellas, Carberry was the vice president of clinical operations, development planning and performance analysis and the office of international development at Genentech. In that role, Carberry developed a global platform for the execution of non-clinical and clinical activities and established many key relationships with company stakeholders. Previously, Carberry was the senior vice president of global clinical operations at Johnson & Johnson Pharmaceutical Research and Development. Dr. Carberry began his industry career with Pharmacia at the Kalamazoo Research site where he held positions of increasing responsibility across the development organization. Carberry earned his M.D. at the University of Nairobi in Kenya and completed his Post Doctoral Fellowship in Clinical Pharmacology at the University of Texas. He earned his M.B.A. at Western Michigan University.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at http://www.astellas.com/en/.


'/>"/>
SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Adds CNS Therapy Area Leader to Global R&D Team
2. Astellas Hires New Vice President of Compliance
3. Astellas Announces New Vice President of Marketing
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
6. FDA Approves Additional Indication for Astellas MYCAMINE(R)
7. Cardiome And Astellas Announce Regulatory Update
8. Spectrum Names Katherine Maynard Chief Operating Officer
9. Sarnova Names Hank Struik Chief Executive Officer
10. Aptium Oncology Names New Chief Operating Officer
11. National Parkinson Foundation Names New Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Dental365 in Levittown opened just a few ... dentistry. Dental365 was established with the patient’s comfort and convenience in mind. ... high-quality, affordable dentistry while offering routine and walk-in emergency dental care 365 days a ...
(Date:5/4/2016)... ... May 05, 2016 , ... “Less than 15% of organizations nationwide can ... “As one of ten non-profit organizations to participate and complete the training, we are ... benefit is that for every $1 we invest in volunteer engagement, we can expect ...
(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the SOCKIT ... trainers to St. Jude Children’s Research Hospital to benefit families dealing with cancer ... designed to teach children how to kick a soccer ball correctly. The device ...
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP ... conference opened on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan ... a deep dive on NCPDP’s model solution to help stem the tide of ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... esteemed Quaker Ridge Golf Club in Scarsdale, New York on May 23, 2016 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology: